USA-based Artisan Pharma and Singapore's A-Bio Pharma have finalized a strategic and mutually-exclusive manufacturing relationship on the process development, scale-up and manufacture of ART-123, a recombinant protein for the treatment of disseminated intravascular coagulation in sepsis.
As part of the deal, A-Bio will undertake the various development and validation activities necessary to ensure further clinical development and commercial supply of ART-123 for Artisan, and, in return, Artisan will enter into a preferential and long-term supply agreement with A-Bio. Specific terms of the relationship were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze